Drug intelligence / Profile preview

NH302

Development stage
Unknown
Lead developer
Jiangsu Nhwa Pharmaceutical
Modality
Small Molecules
Administration
Intravenous, Parenteral
01

Overview

NH302 is a peripherally selective kappa-type opioid receptor agonist developed by Beijing Enhua Pharmaceutical Research Institute, a subsidiary of Enhua Pharmaceutical. It is being developed as a Class 1 innovative chemical drug for the treatment of acute pain. Preclinical studies have demonstrated that NH302 exhibits potent agonistic activity at the kappa-type opioid receptor, showing excellent analgesic efficacy across multiple animal models of pain with a low effective dose, long duration of action, and a wide safety margin for sedation. In August 2026, the National Medical Products Administration (NMPA) of China approved the clinical trial application for NH302 injection to initiate Phase 1 clinical trials for acute pain.

Other names
NH302 injectionNH-302 injectionNH 302 injectionNH302注射液
02

Targets

KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on NH302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NH302.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call